Briefing: Eli Lilly’s ‘triple-G’ shows potency, raises concerns
Strategic angle: Eli Lilly's 'triple-G' drug shows potency, In-vivo CAR-T inches toward clinical reality, and more in today's Readout newsletter.
Browse the full archive, newest first.
Strategic angle: Eli Lilly's 'triple-G' drug shows potency, In-vivo CAR-T inches toward clinical reality, and more in today's Readout newsletter.
Strategic angle: BMW's design director said it would have 'looked too retro.'
Strategic angle: The World Trade Organization predicts a slowdown in global trade growth amid geopolitical tensions.
Strategic angle: Several Republican-led states are passing their own versions of the SAVE America Act, Trump-backed legislation that would introduce new proof-of-citizenship requirements to register to vote.
Strategic angle: The complex brings together manuscripts, research facilities and interactive exhibitions, offering public access to Islamic heritage through education, technology and international collaboration.
Strategic angle: U.S. dealers saw the potent coupe and the AMG G63 Cabriolet.
Strategic angle: Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.
Strategic angle: The former counter-terrorism head resigned on Tuesday over the war with Iran, saying the country posed 'no imminent threat' to the US.